Published in Vaccine on October 11, 2008
The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol (2009) 5.99
HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev (2013) 3.30
Viral shape-shifting: norovirus evasion of the human immune system. Nat Rev Microbiol (2010) 2.53
Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J Virol (2010) 1.89
Vaccines: the fourth century. Clin Vaccine Immunol (2009) 1.61
Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic. J Virol (2009) 1.50
Vaccinology in the genome era. J Clin Invest (2009) 1.31
Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected. J Virol (2011) 1.27
Novel structurally designed vaccine for S. aureus α-hemolysin: protection against bacteremia and pneumonia. PLoS One (2012) 1.20
The key role of genomics in modern vaccine and drug design for emerging infectious diseases. PLoS Genet (2009) 1.18
Progress in HIV-1 vaccine development. Curr Opin HIV AIDS (2013) 1.09
The state of norovirus vaccines. Clin Infect Dis (2014) 1.05
Vaccines, reverse vaccinology, and bacterial pathogenesis. Cold Spring Harb Perspect Med (2013) 1.01
Design and immunogenicity of a novel synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein. Clin Vaccine Immunol (2011) 0.98
Evolution of H3N2 influenza virus in a guinea pig model. PLoS One (2011) 0.97
How can vaccines against influenza and other viral diseases be made more effective? PLoS Biol (2010) 0.96
Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement. Virol J (2012) 0.92
Efficient production of foot-and-mouth disease virus empty capsids in insect cells following down regulation of 3C protease activity. J Virol Methods (2012) 0.92
Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. Virology (2009) 0.92
Vaccines displaying mycobacterial proteins on biopolyester beads stimulate cellular immunity and induce protection against tuberculosis. Clin Vaccine Immunol (2011) 0.89
Strategies to guide the antibody affinity maturation process. Curr Opin Virol (2015) 0.87
Sculpting humoral immunity through dengue vaccination to enhance protective immunity. Front Immunol (2012) 0.87
FcRn overexpression in transgenic mice results in augmented APC activity and robust immune response with increased diversity of induced antibodies. PLoS One (2012) 0.86
Structural analysis of the synthetic Duffy Binding Protein (DBP) antigen DEKnull relevant for Plasmodium vivax malaria vaccine design. PLoS Negl Trop Dis (2015) 0.86
Immunosilencing a highly immunogenic protein trimerization domain. J Biol Chem (2015) 0.85
Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site. Curr Opin HIV AIDS (2013) 0.85
An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site. Vaccine (2011) 0.84
Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles. PLoS One (2012) 0.84
Choice and Design of Adjuvants for Parenteral and Mucosal Vaccines. Vaccines (Basel) (2015) 0.84
Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II. Vaccine (2013) 0.83
Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein. Int J Parasitol (2012) 0.81
Detailed characterization of antibody responses against HIV-1 group M consensus gp120 in rabbits. Retrovirology (2014) 0.81
Epitope dampening monotypic measles virus hemagglutinin glycoprotein results in resistance to cocktail of monoclonal antibodies. PLoS One (2013) 0.81
Antidotes, antibody-mediated immunity and the future of pharmaceutical product development. Hum Vaccin Immunother (2013) 0.80
Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II. Clin Vaccine Immunol (2014) 0.80
Use of Moraxella catarrhalis lipooligosaccharide mutants to identify specific oligosaccharide epitopes recognized by human serum antibodies. Infect Immun (2009) 0.79
Serological characterization of guinea pigs infected with H3N2 human influenza or immunized with hemagglutinin protein. Virol J (2010) 0.79
Developing strategies to enhance and focus humoral immune responses using filamentous phage as a model antigen. Bioeng Bugs (2011) 0.78
Identification and Characterization of msf, a Novel Virulence Factor in Haemophilus influenzae. PLoS One (2016) 0.78
Identifying protective Streptococcus pyogenes vaccine antigens recognized by both B and T cells in human adults and children. Sci Rep (2016) 0.76
Live-virus exposure of vaccine-protected macaques alters the anti-HIV-1 antibody repertoire in the absence of viremia. Retrovirology (2013) 0.76
A Synthetic Virus-Like Particle Streptococcal Vaccine Candidate Using B-Cell Epitopes from the Proline-Rich Region of Pneumococcal Surface Protein A. Vaccines (Basel) (2015) 0.75
Xenoepitope substitution avoids deceptive imprinting and broadens the immune response to foot-and-mouth disease virus. Clin Vaccine Immunol (2012) 0.75
Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets. Hum Vaccin Immunother (2016) 0.75
The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell (2005) 10.61
Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol (2002) 4.63
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol (2003) 3.10
Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol (2008) 2.71
A large set of Finnish affected sibling pair families with type 2 diabetes suggests susceptibility loci on chromosomes 6, 11, and 14. Diabetes (2004) 2.46
Variations in the hemagglutinin of the 2009 H1N1 pandemic virus: potential for strains with altered virulence phenotype? PLoS Pathog (2010) 1.70
Molecular basis of pathogenesis of FMDV. Virus Res (2003) 1.58
Differential contribution of PB1-F2 to the virulence of highly pathogenic H5N1 influenza A virus in mammalian and avian species. PLoS Pathog (2011) 1.49
Foot and mouth disease virus vaccines. Vaccine (2009) 1.36
The leader proteinase of foot-and-mouth disease virus inhibits the induction of beta interferon mRNA and blocks the host innate immune response. J Virol (2006) 1.30
High prevalence of a novel porcine bocavirus in weanling piglets with respiratory tract symptoms in China. Arch Virol (2010) 1.20
Degradation of nuclear factor kappa B during foot-and-mouth disease virus infection. J Virol (2007) 1.20
Fitness of pandemic H1N1 and seasonal influenza A viruses during co-infection: evidence of competitive advantage of pandemic H1N1 influenza versus seasonal influenza. PLoS Curr (2009) 1.19
A 27-amino-acid deletion in the neuraminidase stalk supports replication of an avian H2N2 influenza A virus in the respiratory tract of chickens. J Virol (2010) 1.18
Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine. Virology (2005) 1.18
Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine. Vaccine (2003) 1.13
Novel viral disease control strategy: adenovirus expressing alpha interferon rapidly protects swine from foot-and-mouth disease. J Virol (2003) 1.10
Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein. Curr HIV Res (2007) 1.07
Outbreak of swine influenza in Argentina reveals a non-contemporary human H3N2 virus highly transmissible among pigs. J Gen Virol (2011) 1.04
Short hairpin RNA targeted to the highly conserved 2B nonstructural protein coding region inhibits replication of multiple serotypes of foot-and-mouth disease virus. Virology (2005) 1.03
Evading the host immune response: how foot-and-mouth disease virus has become an effective pathogen. FEMS Immunol Med Microbiol (2008) 1.01
Characterization of duck H5N1 influenza viruses with differing pathogenicity in mallard (Anas platyrhynchos) ducks. Avian Pathol (2009) 0.98
Enhanced antiviral activity against foot-and-mouth disease virus by a combination of type I and II porcine interferons. J Virol (2007) 0.98
A conserved domain in the leader proteinase of foot-and-mouth disease virus is required for proper subcellular localization and function. J Virol (2008) 0.97
Evolution of H3N2 influenza virus in a guinea pig model. PLoS One (2011) 0.97
How can vaccines against influenza and other viral diseases be made more effective? PLoS Biol (2010) 0.96
Induction of foot-and-mouth disease virus-specific cytotoxic T cell killing by vaccination. Clin Vaccine Immunol (2010) 0.96
Constitutive expression of alpha interferon by skin dendritic cells confers resistance to infection by foot-and-mouth disease virus. J Virol (2005) 0.95
Bovine type III interferon significantly delays and reduces the severity of foot-and-mouth disease in cattle. J Virol (2012) 0.94
An adenovirus vectored mucosal adjuvant augments protection of mice immunized intranasally with an adenovirus-vectored foot-and-mouth disease virus subunit vaccine. Vaccine (2013) 0.93
Porcine type I interferon rapidly protects swine against challenge with multiple serotypes of foot-and-mouth disease virus. J Interferon Cytokine Res (2010) 0.91
Antiviral activity of bovine type III interferon against foot-and-mouth disease virus. Virology (2011) 0.90
Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon alpha. Vaccine (2006) 0.90
Delivery of a foot-and-mouth disease virus empty capsid subunit antigen with nonstructural protein 2B improves protection of swine. Vaccine (2008) 0.88
Adenovirus-mediated type I interferon expression delays and reduces disease signs in cattle challenged with foot-and-mouth disease virus. J Interferon Cytokine Res (2003) 0.87
Heightened adaptive immune responses following vaccination with a temperature-sensitive, live-attenuated influenza virus compared to adjuvanted, whole-inactivated virus in pigs. Vaccine (2012) 0.87
Increased efficacy of an adenovirus-vectored foot-and-mouth disease capsid subunit vaccine expressing nonstructural protein 2B is associated with a specific T cell response. Vaccine (2011) 0.87
Systemic mycoplasmosis with dystocia and abortion in a North American bison (Bison bison) herd. J Vet Diagn Invest (2013) 0.86
Unusual history and initial clinical signs of Mycoplasma bovis mastitis and arthritis in first-lactation cows in a closed commercial dairy herd. J Am Vet Med Assoc (2007) 0.86
Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Arch Dermatol (2012) 0.85
In vivo selection of H1N2 influenza virus reassortants in the ferret model. J Virol (2013) 0.85
Selective pressure to increase charge in immunodominant epitopes of the H3 hemagglutinin influenza protein. J Mol Evol (2010) 0.85
Inoculation of swine with foot-and-mouth disease SAP-mutant virus induces early protection against disease. J Virol (2011) 0.84
Differential gene expression in bovine cells infected with wild type and leaderless foot-and-mouth disease virus. Virology (2010) 0.83
Novel antiviral therapeutics to control foot-and-mouth disease. J Interferon Cytokine Res (2012) 0.82
Recombinant PRRSV expressing porcine circovirus sequence reveals novel aspect of transcriptional control of porcine arterivirus. Virus Res (2009) 0.81
The presence of alpha interferon at the time of infection alters the innate and adaptive immune responses to porcine reproductive and respiratory syndrome virus. Clin Vaccine Immunol (2012) 0.81
Deletions in the neuraminidase stalk region of H2N2 and H9N2 avian influenza virus subtypes do not affect postinfluenza secondary bacterial pneumonia. J Virol (2012) 0.81
Epitope dampening monotypic measles virus hemagglutinin glycoprotein results in resistance to cocktail of monoclonal antibodies. PLoS One (2013) 0.81
Antibody repertoire development in fetal and neonatal piglets XXI. Usage of most VH genes remains constant during fetal and postnatal development. Mol Immunol (2011) 0.80
Venezuelan equine encephalitis replicon particles can induce rapid protection against foot-and-mouth disease virus. J Virol (2013) 0.80
Serological characterization of guinea pigs infected with H3N2 human influenza or immunized with hemagglutinin protein. Virol J (2010) 0.79
HIV-1: the confounding variables of virus neutralization. Curr Drug Targets Infect Disord (2005) 0.78
Antibody neutralization of retargeted measles viruses. Virology (2014) 0.78
Type III interferon protects swine against foot-and-mouth disease. J Interferon Cytokine Res (2014) 0.77
What role do periodontal pathogens play in osteoarthritis and periprosthetic joint infections of the knee? J Appl Biomater Funct Mater (2014) 0.76
Perspectives on advancing preventative medicine through vaccinology at the comparative veterinary, human and conservation medicine interface: not missing the opportunities. Vaccine (2008) 0.76
Characterization of cytotoxic T lymphocyte function after foot-and-mouth disease virus infection and vaccination. Viral Immunol (2013) 0.76
Effect of the XRCC1 codon 399 polymorphism on the repair of vinyl chloride metabolite-induced DNA damage. J Carcinog (2009) 0.76
Advances in immunology and vaccine discovery report of the United States-European Commission workshop. Vaccine (2007) 0.75
[Virulence changes of H5N1 avian influenza virus after gene reassortment]. Wei Sheng Wu Xue Bao (2008) 0.75
Exchange and sharing of new information, experiences, and approaches to controlling, reducing, and eventually eradicating different types of diseases. Conclusion. Vaccine (2010) 0.75
The feasibility of external blind DNA proficiency testing. I. Background and findings. J Forensic Sci (2003) 0.75
The feasibility of external blind DNA proficiency testing. II. Experience with actual blind tests. J Forensic Sci (2003) 0.75
Susceptibility of swine cells and domestic pigs to SARS-CoV-2. bioRxiv (2020) 0.75